News Details

(Enabling Pharmacokinetic (PK), Vaccine, CAR-T, and Gene Therapy Studies)

Why Non-Human Primate Models Are Critical for Predicting Human Therapeutic Outcomes 

Traditional rodent models, while instrumental in early-stage drug discovery, often fall short in predicting human responses to complex biologics. This translational gap contributes significantly to high clinical attrition rates, where promising preclinical candidates encounter unforeseen safety concerns or fail to demonstrate efficacy in human trials.

Non-human primates (NHPs), particularly Rhesus monkeys, offer a critical solution. Their close phylogenetic relationship to humans, along with comparable anatomical, physiological, and immunological characteristics, makes them uniquely suited for evaluating novel therapeutics. This is especially vital for advanced modalities such as monoclonal antibodies, gene therapies, and cell-based treatments, where species-specific differences can profoundly influence therapeutic outcomes.

Advancing Preclinical Research Through NHP Model Infrastructure- @ Palamur Biosciences

Palamur Biosciences (PBS) has established a state-of-the-art NHP research facility designed to support a wide range of preclinical studies. This specialized infrastructure enables comprehensive evaluations across multiple therapeutic areas—from routine pharmacokinetic assessments to complex gene therapy and vaccine efficacy trials.

By offering an integrated platform for complete preclinical programs, PBS significantly enhances India’s research capabilities. This domestic infrastructure allows Indian biotechnology companies to conduct end-to-end studies without the logistical and regulatory complexities of international outsourcing. Simultaneously, PBS provides global pharmaceutical companies with access to cost-effective, high-quality research services.

Specialized Preclinical Capabilities of Palamur Biosciences: From Targeted Delivery to CAR-T Evaluation

PBS offers a broad spectrum of advanced dosing and delivery techniques, ensuring precise and reproducible administration of investigational therapies:

• Conventional Routes: Oral, intravenous, subcutaneous, and intramuscular
• Neuro-targeted Delivery: Intrathalamic, transcisternal, transpinal, epidural, and perineural
• Gastrointestinal Procedures: Direct gastric lavage and transgastric dosing
• Ocular Techniques: Intracameral and intravitreal administration
• CAR-T Cell Therapy Platform -Palamur Biosciences has developed a robust CAR-T cell therapy evaluation platform that meets global regulatory standards. This includes:
  • Efficacy Assessment: Utilizing NOD-scid-gamma (NSG) mouse models engrafted with human tumours to assess anti-tumour activity, potency, and persistence of CAR-T constructs.
  • Safety Evaluation: Conducting studies in Rhesus monkeys to gain critical insights into therapy behaviour in a fully immunocompetent system. These studies address key regulatory requirements such as:
    • Detailed toxicity profiling
    • Immunogenicity characterization
    • Biodistribution analysis
    • Long-term persistence monitoring

The close genetic similarity between Rhesus/Cynomolgus monkeys and humans ensures that safety data generated at PBS is highly translatable to clinical settings.

Rhesus or Cynomolgus ?

Rhesus and Cynomolgus CAR-T specific targets have 100% homology between them. The close genetic similarity between Rhesus and Cynomolgus monkeys and humans makes them highly relevant models for evaluating the safety of advanced therapies. At PBS, the safety data generated using these nonhuman primates is therefore highly translatable to clinical settings. Importantly, Rhesus and Cynomolgus monkeys share 100% homology with humans for CAR-T specific targets, further reinforcing the predictive value of these models in preclinical development

Regulatory Compliance and Ethical Standards in Preclinical Research.

At PBS Palamur Biosciences operates under Good Laboratory Practice (GLP) certification and holds AAALAC and OLAW accreditations, reflecting its adherence to the highest international standards and facilitating regulatory submissions such as  FDA/EMA. The organization is deeply committed to ethical research practices, guided by the principles of the Committee for the Control and Supervision of Experiments on Animals (CCSEA).

PBS ensures that all animal studies are conducted with compassion, responsibility, and transparency, upholding the highest standards of animal welfare while delivering scientifically robust data and also maintained through continuous training programs  and oversights .

Conclusion

Non-human primate models are indispensable in bridging the gap between preclinical research and human clinical trials, especially for biologics and next-generation therapies. Palamur Biosciences is leading this transformation by offering a comprehensive, ethically grounded, and scientifically rigorous NHP research platform. By enabling high-quality preclinical studies within India, PBS accelerates drug development timelines and empowers both domestic and global innovators to deliver safer, more effective treatments to patients worldwide.